You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study

Article metrics

Article menu

Download PDFPDF

XML
Immune cell therapies and immune cell engineering
Original research
Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study

 

Online download statistics by month:

Online download statistics by month: April 2020 to July 2025

AbstractFullPdf
Apr 2020459459237
May 202030430440
Jun 2020363617
Jul 2020414113
Aug 2020414015
Sep 2020404013
Oct 2020303017
Nov 202025247
Dec 202026264
Jan 2021343414
Feb 2021393911
Mar 2021434313
Apr 202128287
May 2021252516
Jun 202132337
Jul 2021202011
Aug 2021131334
Sep 2021343447
Oct 2021292935
Nov 2021363627
Dec 202120207
Jan 2022414213
Feb 2022151612
Mar 2022464613
Apr 202244498
May 2022434418
Jun 2022393913
Jul 2022394023
Aug 2022393924
Sep 2022313232
Oct 2022404218
Nov 2022303221
Dec 2022282810
Jan 202322229
Feb 202345457
Mar 2023222312
Apr 2023383810
May 2023313210
Jun 202323237
Jul 202316198
Aug 2023181915
Sep 2023414214
Oct 2023293012
Nov 2023404121
Dec 202343438
Jan 2024242511
Feb 2024474824
Mar 2024343426
Apr 2024292921
May 202422238
Jun 2024434314
Jul 2024353611
Aug 2024404015
Sep 2024404321
Oct 2024323220
Nov 2024404114
Dec 2024556113
Jan 2025585819
Feb 202510610614
Mar 2025323223
Apr 2025535415
May 2025303129
Jun 2025232416
Jul 2025110
Total290229411244